Overview

A Study on Bioequivalence of Cabergoline Tablets in Human Body

Status:
RECRUITING
Trial end date:
2026-05-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the bioequivalence of the test formulation and reference formulation of cabergoline tablets in healthy Chinese subjects under fasting and postprandial conditions.
Phase:
PHASE1
Details
Lead Sponsor:
Changchun GeneScience Pharmaceutical Co., Ltd.
Treatments:
Cabergoline